공시 • May 16
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026. 공시 • May 09
Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026 공시 • Mar 26
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury. 공시 • Jan 08
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026.
The expected completion of the transaction is March 31, 2026. 공시 • Dec 04
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026 공시 • Aug 28
Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025 공시 • Jun 03
Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Aug 06, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Aug 06, 2025 공시 • May 13
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025. 공시 • Mar 01
Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on May 13, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on May 13, 2025 공시 • Feb 27
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million. Rohto Pharmaceutical Co., Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its issued share capital, for a total cost of up to ¥5,000 million. The plan will continue until April 30, 2025. 공시 • Feb 26
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its share capital, for ¥5,000 million. The purpose of the program is to improve ROE and earnings per share (EPS), mitigate the short-term impact on the supply and demand of its shares from the issuance of Euro-yen convertible bonds with stock acquisition rights due in 2032, and facilitate fund procurement. The program will expire on April 30, 2025. As of December 31, 2024, the company had 228,138,738 shares in issue (excluding treasury stock) and 8,039,572 shares in treasury. 공시 • Feb 12
Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025 Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the fiscal Year Ending March 31, 2025. For the year, the company expects dividend of JPY 20.00 per share compared to JPY 17.00 per share a year ago. Reasons for the revisions: Consistently and continually returning to shareholders the profits earned through business activities is one of the highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by JPY 3 to JPY 20 per share. As such, the total annual dividend will be JPY 36 per share. 공시 • Nov 29
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Feb 12, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025 공시 • Aug 28
Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2025 results on Nov 13, 2024 공시 • Jun 17
Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024 공시 • Jun 08
Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million. Rohto Pharmaceutical Co.,Ltd. agreed to acquire additional 51% stake in Mono chem-pharm Produkte Gmbh for €30 million on June 6, 2024. 공시 • May 15
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024. 공시 • May 11
Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q4, 2024 results on May 13, 2024 공시 • Apr 05
Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million on April 4, 2024. Eu Yan Sang International has net assets of SGD 149.9 million, total assets of SGD 268.1 million, sales of SGD 297.3 million, net income of SGD 18.7 million and core EBITDA of SGD 42.2 million as of June 30, 2023. Upon the fulfillment of the condition to the Share Acquisition, we will conduct a mandatory general offer for the remaining 14% of the issued ordinary shares of EYS The transaction is expected to complete by June 30, 2024. 공시 • Dec 28
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024 공시 • Nov 12
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. The company expects net sales to be JPY 270,000 million, Operating profit to be JPY 38,500 million, profit attributable to owners of parent to be JPY 29,000 million or JPY 127.12 per basic share. 공시 • Oct 01
Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023 공시 • Jul 06
Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023 공시 • May 14
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023. 공시 • Jan 09
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023